Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
In this study, researchers are assessing the safety and effectiveness of giving the drug disitamab vedotin alone and in combination with pembrolizumab immunotherapy in people with inoperable or metastatic urothelial cancers that make too much of the HER2 protein. Disitamab vedotin targets and kills cancer cells with the HER2 protein. Pembrolizumab boosts the power of the immune system to detect and destroy cancer cells.
Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient's stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient's immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
Chemotherapy can cause symptoms, such as nausea and fatigue, and some patients have difficulty working during this treatment. The purpose of this study is to learn more about how chemotherapy for breast cancer affects patients' employment.
Researchers want to learn if canakinumab can prevent cancer from developing in people with clonal cytopenia of undetermined significance (CCUS). In CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells.
People with early-stage breast cancer who undergo lumpectomy have traditionally also received radiation therapy and hormonal (endocrine) therapy to reduce their risk of breast cancer recurrence. Doctors want to know if some patients with low-risk early-stage breast cancer can forgo radiation therapy (which takes several weeks and has side effects) and do as well if they receive only hormonal therapy after lumpectomy.
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
Researchers are comparing combination chemotherapy alone or with a stem cell transplant for people with amyloid light chain (AL) amyloidosis. The people in this study have newly diagnosed AL amyloidosis. The chemotherapy includes daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD).
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
